SCHEMBL17872140

SCHEMBL17872140

COC(=O)CCCNC(=O)C(CCCNCCCNC(=O)OCc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 2/20 0.53
KLK5 Q9Y337 2/20 0.53
MAPT P10636 1/20 0.53
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
CPB1 P15086 1/20 0.49
CPB2 Q96IY4 1/20 0.49
CAPN1 P07384 1/20 0.49
CAPN2 P17655 1/20 0.49
CTSS P25774 2/20 0.48
CTSK P43235 1/20 0.48
PTGER4 P35408 1/20 0.48
CTSL P07711 1/20 0.48
HTT P42858 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
SIRT3 Q9NTG7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17872138 0.96 MAPT (0.56) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL5651760 0.93 MAPT (0.57) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL19732585 0.89 KLK7 (0.55) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL17872143 0.87 KLK7 (0.52) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL30859242 0.86 MAPT (0.62) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL29454880 0.86 MAPT (0.60) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL12085041 0.86 MAPT (0.62) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL12667695 0.86 MAPT (0.59) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL5996732 0.86 CTSK (0.61) KLK7KLK5MAPTITGB3ITGA2B
SCHEMBL4857149 0.86 MAPT (0.58) KLK7KLK5MAPTCPB1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10434186-B2 Functionalized linear ligands and complexes thereof LUMIPHORE, INC. (US) 2019-10-08 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
EP-3237429-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF Lumiphore, Inc. (US) 2017-11-01 EP disclosed
WO-2016106241-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF CLTB, CLTA, EPCAM KLK7 1145/4885KLK5 1322/4885MAPT 1163/4885
US-10434186-B2 Functionalized linear ligands and complexes thereof CLTB, CLTA, EPCAM KLK7 1145/4885KLK5 1322/4885MAPT 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.